Article
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro-oncology - 1 Mar 2011
Sampson John H, Aldape Kenneth D, Archer Gary E, Coan April, Desjardins Annick, Friedman Allan H, Friedman Henry S, Gilbert Mark R, Herndon James E, McLendon Roger E, Mitchell Duane A, Reardon David A, Sawaya Raymond, Schmittling Robert, Shi Weiming, Vredenburgh James J, Bigner Darell D, Heimberger Amy B
Abstract excerpt
Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic cells more precisely but may be inhibited by concurrent myelosuppressive chemotherapy like temozolomide (TMZ), which produces a survival benefit in GBM. A phase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.